vs

Side-by-side financial comparison of LandBridge Co LLC (LB) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

LandBridge Co LLC is the larger business by last-quarter revenue ($56.8M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). LandBridge Co LLC runs the higher net margin — 14.2% vs -304.2%, a 318.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 55.6%). LandBridge Co LLC produced more free cash flow last quarter ($122.0M vs $-47.3M). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (72.8% CAGR vs 60.5%).

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

LB vs RXRX — Head-to-Head

Bigger by revenue
LB
LB
1.6× larger
LB
$56.8M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+626.2% gap
RXRX
681.7%
55.6%
LB
Higher net margin
LB
LB
318.4% more per $
LB
14.2%
-304.2%
RXRX
More free cash flow
LB
LB
$169.4M more FCF
LB
$122.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
LB
LB
Annualised
LB
72.8%
60.5%
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LB
LB
RXRX
RXRX
Revenue
$56.8M
$35.5M
Net Profit
$8.1M
$-108.1M
Gross Margin
59.8%
Operating Margin
60.0%
-304.8%
Net Margin
14.2%
-304.2%
Revenue YoY
55.6%
681.7%
Net Profit YoY
-83.7%
39.6%
EPS (diluted)
$0.24
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LB
LB
RXRX
RXRX
Q4 25
$56.8M
$35.5M
Q3 25
$50.8M
$5.2M
Q2 25
$47.5M
$19.2M
Q1 25
$44.0M
$14.7M
Q4 24
$36.5M
$4.5M
Q3 24
$28.5M
$26.1M
Q2 24
$26.0M
$14.4M
Q1 24
$19.0M
$13.8M
Net Profit
LB
LB
RXRX
RXRX
Q4 25
$8.1M
$-108.1M
Q3 25
$8.1M
$-162.3M
Q2 25
$7.5M
$-171.9M
Q1 25
$6.5M
$-202.5M
Q4 24
$49.3M
$-178.9M
Q3 24
$2.7M
$-95.8M
Q2 24
$-57.7M
$-97.5M
Q1 24
$10.8M
$-91.4M
Gross Margin
LB
LB
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
LB
LB
RXRX
RXRX
Q4 25
60.0%
-304.8%
Q3 25
60.8%
-3327.6%
Q2 25
60.0%
-916.8%
Q1 25
57.0%
-1297.9%
Q4 24
49.4%
-4042.4%
Q3 24
11.2%
-377.1%
Q2 24
-197.4%
-697.4%
Q1 24
71.1%
-698.4%
Net Margin
LB
LB
RXRX
RXRX
Q4 25
14.2%
-304.2%
Q3 25
15.9%
-3135.3%
Q2 25
15.8%
-894.2%
Q1 25
14.7%
-1373.3%
Q4 24
135.2%
-3935.5%
Q3 24
9.3%
-367.5%
Q2 24
-222.1%
-676.6%
Q1 24
56.7%
-662.4%
EPS (diluted)
LB
LB
RXRX
RXRX
Q4 25
$0.24
$-0.17
Q3 25
$0.26
$-0.36
Q2 25
$0.24
$-0.41
Q1 25
$0.20
$-0.50
Q4 24
$-0.56
Q3 24
$-0.04
$-0.34
Q2 24
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LB
LB
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$30.7M
$743.3M
Total DebtLower is stronger
$570.7M
$9.6M
Stockholders' EquityBook value
$340.3M
$1.1B
Total Assets
$1.4B
$1.5B
Debt / EquityLower = less leverage
1.68×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LB
LB
RXRX
RXRX
Q4 25
$30.7M
$743.3M
Q3 25
$28.3M
$659.8M
Q2 25
$20.3M
$525.1M
Q1 25
$14.9M
$500.5M
Q4 24
$37.0M
$594.4M
Q3 24
$14.4M
$427.6M
Q2 24
$24.6M
$474.3M
Q1 24
$296.3M
Total Debt
LB
LB
RXRX
RXRX
Q4 25
$570.7M
$9.6M
Q3 25
$366.1M
$11.9M
Q2 25
$370.9M
$14.2M
Q1 25
$375.5M
$16.4M
Q4 24
$385.5M
$19.0M
Q3 24
$242.4M
$20.5M
Q2 24
$360.8M
$22.9M
Q1 24
Stockholders' Equity
LB
LB
RXRX
RXRX
Q4 25
$340.3M
$1.1B
Q3 25
$272.0M
$1.0B
Q2 25
$266.4M
$919.1M
Q1 25
$217.0M
$933.9M
Q4 24
$211.8M
$1.0B
Q3 24
$97.2M
$524.6M
Q2 24
$296.4M
$584.4M
Q1 24
$162.3M
$401.2M
Total Assets
LB
LB
RXRX
RXRX
Q4 25
$1.4B
$1.5B
Q3 25
$1.1B
$1.4B
Q2 25
$1.1B
$1.3B
Q1 25
$1.0B
$1.3B
Q4 24
$1.0B
$1.4B
Q3 24
$689.9M
$726.5M
Q2 24
$710.5M
$775.9M
Q1 24
$557.8M
Debt / Equity
LB
LB
RXRX
RXRX
Q4 25
1.68×
0.01×
Q3 25
1.35×
0.01×
Q2 25
1.39×
0.02×
Q1 25
1.73×
0.02×
Q4 24
1.82×
0.02×
Q3 24
2.49×
0.04×
Q2 24
1.22×
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LB
LB
RXRX
RXRX
Operating Cash FlowLast quarter
$126.3M
$-46.1M
Free Cash FlowOCF − Capex
$122.0M
$-47.3M
FCF MarginFCF / Revenue
214.9%
-133.1%
Capex IntensityCapex / Revenue
7.5%
3.5%
Cash ConversionOCF / Net Profit
15.68×
TTM Free Cash FlowTrailing 4 quarters
$207.7M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LB
LB
RXRX
RXRX
Q4 25
$126.3M
$-46.1M
Q3 25
$34.9M
$-117.4M
Q2 25
$37.3M
$-76.4M
Q1 25
$15.9M
$-132.0M
Q4 24
$67.6M
$-115.4M
Q3 24
$7.5M
$-59.2M
Q2 24
$16.0M
$-82.2M
Q1 24
$17.2M
$-102.3M
Free Cash Flow
LB
LB
RXRX
RXRX
Q4 25
$122.0M
$-47.3M
Q3 25
$33.7M
$-117.6M
Q2 25
$36.1M
$-79.6M
Q1 25
$15.8M
$-133.8M
Q4 24
$66.7M
$-116.7M
Q3 24
$7.1M
$-63.8M
Q2 24
$15.7M
$-83.4M
Q1 24
$17.1M
$-109.0M
FCF Margin
LB
LB
RXRX
RXRX
Q4 25
214.9%
-133.1%
Q3 25
66.3%
-2272.5%
Q2 25
75.9%
-413.9%
Q1 25
36.0%
-907.4%
Q4 24
182.6%
-2567.7%
Q3 24
25.1%
-244.6%
Q2 24
60.4%
-578.5%
Q1 24
90.1%
-789.9%
Capex Intensity
LB
LB
RXRX
RXRX
Q4 25
7.5%
3.5%
Q3 25
2.3%
4.7%
Q2 25
2.6%
16.4%
Q1 25
0.2%
12.4%
Q4 24
2.7%
28.6%
Q3 24
1.1%
17.5%
Q2 24
1.4%
8.2%
Q1 24
0.5%
48.2%
Cash Conversion
LB
LB
RXRX
RXRX
Q4 25
15.68×
Q3 25
4.31×
Q2 25
4.98×
Q1 25
2.46×
Q4 24
1.37×
Q3 24
2.80×
Q2 24
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons